❤️ Statin Therapy Initiation Threshold Simulator

Entering the Calculated 10-Year ASCVD Risk Score

A single risk-equation output starts the entire initiation decision.

• Pooled Cohort Eq.: Risk tool (ACC/AHA risk calculator)
• 40–75 yrs: Validated age range (Primary prevention population)
• 7 variables: Inputs used (Age, sex, lipids, BP, smoking, diabetes)
• 10-yr % risk: Output (Continuous risk estimate)

Where the risk number comes from

A short placeholder: risk equation output feeds this simulator directly.

Placing Risk Into Low, Borderline, Intermediate, or High Zones

Four guideline zones split the risk scale at fixed cut points.

• <5%: Low zone (Statin not routinely indicated)
• 5–7.5%: Borderline zone (Enhancers may tip decision)
• 7.5–20%: Intermediate zone (Shared decision-making zone)
• ≥20%: High zone (Statin strongly recommended)

How the zone boundaries were set

A short placeholder: cut points come from outcome-trial risk stratification.

Checking Risk-Enhancing Factors Beyond the Base Score

Extra clinical flags refine decisions in borderline and intermediate cases.

• Premature ASCVD: Family history (Risk-enhancer flag)
• ≥2.0 mg/L: hs-CRP (Risk-enhancer flag)
• CAC score >0: Coronary calcium (Risk-enhancer flag)
• Present: Metabolic syndrome (Risk-enhancer flag)

Why enhancers matter at the margins

A short placeholder: enhancers tip borderline patients toward treatment.

Shared Decision-Making Within the Intermediate Risk Band

Patient preference and enhancers jointly guide the intermediate-zone call.

• 7.5–20%: Applicable range (Intermediate risk band)
• Benefits vs risks: Discussion topics (Bleeding, myalgia, cost)
• Yes: Enhancer tiebreaker (Tips toward statin use)
• Weighted input: Patient preference (Final decision factor)

What the shared discussion covers

A short placeholder: clinician and patient weigh risk and preference together.

Issuing the Statin Initiation and Intensity Recommendation

Combined risk zone and enhancer count yield one clear recommendation.

• High-intensity: High risk (≥20% 10-year risk)
• Moderate: Intermediate + enhancers (Statin favored)
• Not indicated: Low risk (Unless enhancers present)
• Lipid recheck: Follow-up (4–12 weeks after start)

Reading the final recommendation

A short placeholder: recommendation strength scales with risk and enhancers.

This tool supports, not replaces, individualized clinician judgment.